Pulse Biosciences (Nasdaq:PLSE) announced today that it entered into a collaboration with CardioNXT to support its AFib treatment.
The collaboration supports Pulse Biosciences’ planned first-in-human study of its pulsed-field ablation technology. Hayward, California-based Pulse develops a proprietary nanosecond pulsed-field ablation (nsPFA) cardiac catheter to treat AFib.
Pulse and CardioNXT plan for their partnership to integrate the nsPFA catheter and the CardioNXT iMap navigation and mapping system. This enables electrophysiologists to successfully visualize individual cardiac structures when using the integrated platforms. They can then place the catheter for circumferential ablations of targeted pulmonary veins in AFib treatment.
CardioNXT CEO Jerome Edwards said in a news release that Pulse’s nsPFA technology provides “a highly differentiated” solution. He said integrating systems could enable fast, effective and safe zero-fluoro ablation of cardiac tissue.
The company struck a similar deal with pulsed-field ablation technology developer Field Medical last year. CardioNXT and Field Medical — founded by Farapulse founder Dr. Steven Mickelsen — teamed up to provide a purpose-built PFA therapy integrated with 3D mapping and navigation.
“We are excited to announce this collaboration and the progress we’ve made integrating our circumferential nsPFA catheter with the CardioNXT iMap System,” said Kevin Danahy, CEO of Pulse Biosciences. “The CardioNXT navigation and mapping system was our top choice for integration with our novel nsPFA cardiac circumferential catheter. Their iMap system offers dynamic referencing to provide superior accuracy and stability when navigating our catheter to targeted tissue areas. We’re on track to initiate our first-in-human study in the first half of next year and believe this combination has the potential to achieve best-in-class clinical outcomes.”